In its only precedential patent opinion last week, the Federal Circuit affirmed a preliminary injunction that largely prohibits the use, manufacture, or sale of NeoGenomics’ “RaDaR” assay for cancer remission, and agreed that Natera had shown a likelihood of success on its claim that RaDaR had infringed its U.S. Patent No. 11,519,035. In its opinion, the Court discussed considerations relating to Natera’s likelihood of success, irreparable harm, and the public interest. Among other items, the Court provided noteworthy guidance on an accused infringer’s burden to show invalidity at the preliminary injunction stage, as well as how an injunction may be tailored to avoid public harm when it prohibits the use or sale of healthcare products.
Wyatt Pc is a journalist writing for JD Supra. His articles focus on legal and regulatory updates, particularly in the areas of employment law, federal contracting, and labor relations. Wyatt provides analysis and summaries of recent court cases and developments that impact businesses and workers.